Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NuVasive Selling Titanium-Based Precice Orthopedic Devices Again, Launches Recall To Update IFU

Meanwhile, steel-based Precice devices are still under a July recall action and remain off the market

Executive Summary

NuVasive Inc. is marketing its Precice specialized orthopedic devices made of titanium once again after voluntarily pulling them from the market in April over concerns about the safety of the steel-based version of the product. The firm also initiated a recall to address changes in the instructions for use for titanium Precice.

You may also be interested in...



JPM 2022: Boston Scientific, Inspire, Nuvasive, Vericel

The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022 as they continue to cope with the impact of the Omicron surge. Here are some of the highlights from the presentations on the third day of the meeting.

NuVasive Recalls Orthopedics Implants Over Biocompatibility Concerns

The US FDA says the company has voluntarily issued a recall for Precice metal implants after reports of adverse events that could be related to the design of the product or biocompatibility issues.

Speaking Of Medtech, Ep. 10: FDA’s TAP Pilot

In this FINAL EPISODE of Speaking Of Medtech: The US FDA got something it desperately wanted in its latest user-fee package with industry: a Total Product Lifecycle Advisory Program pilot, or TAP. The agency says TAP will allow for earlier and more frequent engagement with developers – but is it needed?

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT144793

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel